Mirum Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $49
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Mirum Pharmaceuticals' Volixibat Gets Breakthrough Therapy Designation From FDA
Express News | Mirum Pharmaceuticals Inc: Confirmatory Portion of Study Is Ongoing With Completion of Enrollment Expected in 2026
Express News | Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
When Can We Expect A Profit From Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)?
Mirum Pharmaceuticals Director Buys Shares Worth $4,301
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
Insiders At Mirum Pharmaceuticals Sold US$623k In Stock, Alluding To Potential Weakness
Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating
Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Mirum Pharmaceuticals (MIRM) Receives a Buy From Evercore ISI
Optimistic Buy Rating for Mirum Pharmaceuticals Amidst Strong Sales Growth and Expanded LIVMARLI Label
Mirum Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $44
Express News | Mirum Pharmaceuticals Inc : Baird Raises Target Price to $44 From $39
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals | 10-Q: Q2 2024 Earnings Report